Fig. 7.
Beneficial effects of dasatinib are not CD8-mediated. A. Melc5 CTL were pre- treated with PBS ± 50 nM dasatinib for 30 min at 37 °C, then stained with HLA A2 DT227/8KA cognate tetramer for 20 min at 37 °C. After washing twice, data were acquired on a FACSCalibur flow cytometer (BD) and analyzed using FlowJo software. B. Staining of HLA A2-restricted CTL lines expanded from PBMC by one round of stimulation with the Melan-A/Mart-126-35 peptide (ELAGIGILTV). Lines were stained with either wild type or CD8 null cognate tetramer ± pre-treatment with 50 nM dasatinib for 30 min at 37 °C.